Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions

Autor:	Kathryn E. Flynn, Kelly L. Schoenbeck
Rok vydání:	2021
Předmět:	Oncology Cancer Research medicine.medical_specialty Hematology business.industry Cancer Myeloid leukemia Cognition medicine.disease humanities Discontinuation law.invention Quality of life Randomized controlled trial law hemic and lymphatic diseases Internal medicine Cohort medicine business
Zdroj:	Current Hematologic Malignancy Reports. 16:491-499
ISSN:	1558-822X 1558-8211
DOI:	10.1007/s11899-021-00656-y
Popis:	Tyrosine kinase inhibitors (TKIs) allow many patients with chronic myeloid leukemia (CML) to live normal life spans but have the potential to impact patients’ health-related quality of life (HRQOL). Patient-reported outcome (PRO) measures can provide valuable information to inform treatment decision-making. Here, we review pivotal studies that used PRO measures to evaluate HRQOL of patients with CML in the first-line and treatment-free remission (TFR), and identify areas for future research. PRO measures commonly studied in patients with CML include the SF-36, FACT-Leu, EORTC QLQ-CML24, and MDASI CML. Cohort or cross-sectional studies provide the most data on PRO measures in patients with CML, with less information available from randomized controlled trials (RCTs). Patients with CML taking TKIs have worse HRQOL compared to matched controls, with a few studies seeing a larger effect in younger patients (
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::20c89da89631f62af81a70b033240256 https://doi.org/10.1007/s11899-021-00656-y Zobrazit plný text záznamu Full text from SpringerLink